- Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway “Dysregulated activation of the complement ...
“Our CAN106 program for complement-mediated diseases is gaining momentum this year with the first public presentation of the Phase 1 clinical trial results at two major scientific conferences and the ...
Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. The complement inhibitors are the latest ...
REDWOOD CITY, Calif. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Kriya Therapeutics, Inc., a fully integrated company pioneering novel technologies and therapeutics in gene therapy, today ...
Neurological diseases are conditions that affect your nervous system. Your nervous system includes your brain and spinal cord as well as all the nerves that branch out to the rest of your body. There ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback